Data / Drug companies / Lithium carbonate
Lithium carbonate: 24 companies and 73 products in the FDA NDC directory
Lithium carbonate is listed in the FDA National Drug Code Directory by 24 companies, with 73 products in commercial distribution. 52 of the products (71.2%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are capsule; tablet, extended release; capsule, gelatin coated, and the newest product started marketing on August 16, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 24
- Products
- 73
- Generic (ANDA) products
- 52 (71.2%)
- Application numbers
- 16
- Routes
- Oral
- Brand names
- Lithium Carbonicum, Lithobid
- openFDA record search
- api.fda.gov
Companies that list lithium carbonate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Hikma Pharmaceuticals USA Inc. | 13 | capsule, gelatin coated; tablet | New drug applications (NDA) | August 16, 2026 |
| Remedyrepack Inc. | 13 | capsule; tablet, extended release | Generic drugs (ANDA) | June 19, 2026 |
| Glenmark Pharmaceuticals Inc., USA | 5 | capsule; tablet | Generic drugs (ANDA) | February 14, 2011 |
| PD-Rx Pharmaceuticals, Inc. | 5 | capsule, gelatin coated; tablet, extended release | New drug applications (NDA) | October 28, 2004 |
| Alembic Pharmaceuticals Inc. | 4 | capsule; tablet, extended release | Generic drugs (ANDA) | February 21, 2017 |
| Alembic Pharmaceuticals Limited | 4 | capsule; tablet, extended release | Generic drugs (ANDA) | February 21, 2017 |
| Coupler LLC | 4 | capsule; tablet, film coated, extended release | Generic drugs (ANDA) | August 3, 2026 |
| Camber Pharmaceuticals, Inc. | 3 | capsule | Generic drugs (ANDA) | December 15, 2009 |
| A-S Medication Solutions | 2 | tablet, film coated, extended release | Generic drugs (ANDA) | July 2, 2012 |
| American Health Packaging | 2 | tablet, extended release | Generic drugs (ANDA) | October 13, 2014 |
| American Health Packaging | 2 | capsule | Generic drugs (ANDA) | June 14, 2026 |
| Boiron | 2 | pellet | Unapproved homeopathic products | March 3, 1983 |
| Bryant Ranch Prepack | 2 | capsule | Generic drugs (ANDA) | December 15, 2009 |
| Rising Pharma Holdings, Inc. | 2 | tablet, extended release | Generic drugs (ANDA) | March 1, 2018 |
| Ani Pharmaceuticals, Inc. | 1 | tablet, film coated, extended release | New drug applications (NDA) | July 1, 2014 |
| Aphena Pharma Solutions - Tennessee, LLC | 1 | capsule | Generic drugs (ANDA) | December 15, 2009 |
| AvKARE | 1 | tablet | Generic drugs (ANDA) | February 25, 2022 |
| Boswell Pharmacy Services LLC D/B/A BPS Wholesale | 1 | capsule | Generic drugs (ANDA) | August 21, 2024 |
| Cardinal Health 107, LLC | 1 | capsule, gelatin coated | New drug applications (NDA) | July 28, 1987 |
| Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc. | 1 | tablet, film coated, extended release | Generic drugs (ANDA) | October 20, 2020 |
| NCS HealthCare of Ky, LLC DBA Vangard Labs | 1 | capsule | Generic drugs (ANDA) | February 3, 2009 |
| PD-Rx Pharmaceuticals, Inc. | 1 | tablet, extended release | Generic drugs (ANDA) | January 13, 2004 |
| Proficient Rx LP | 1 | capsule | Generic drugs (ANDA) | December 15, 2009 |
| Sun Pharmaceutical Industries, Inc. | 1 | tablet | Generic drugs (ANDA) | July 8, 2010 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 26 | 35.6% |
| Tablet, extended release | 15 | 20.5% |
| Capsule, gelatin coated | 13 | 17.8% |
| Tablet | 10 | 13.7% |
| Tablet, film coated, extended release | 7 | 9.6% |
| Pellet | 2 | 2.7% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 52 | 71.2% |
| New drug applications (NDA) | 19 | 26% |
| Unapproved homeopathic products | 2 | 2.7% |
Pharmacologic classes
| Class | Products |
|---|---|
| Mood Stabilizer | 73 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.